In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis

被引:140
作者
Chesire, DR
Ewing, CM
Gage, WR
Isaacs, WB
机构
[1] Johns Hopkins Med Inst, Brady Urol Inst Res Labs, Baltimore, MD 21287 USA
[2] Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA
关键词
beta-catenin; prostate cancer; nuclear staining; T cell factor; androgen receptor;
D O I
10.1038/sj.onc.1205352
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Understanding the molecular etiology of prostate cancer (CaP) progression is paramount for broadening current diagnostic and therapeutic modalities. Current interest in the role of wnt pathway signaling in prostate tumorigenesis was generated with the finding of beta-catenin mutation and corresponding nuclear localization in primary lesions. The recent finding of beta-catenin-induced enhancement of androgen receptor (AR) function potentially ties beta-catenin to key regulatory steps of prostate cell growth, differentiation, and transformation. By immunohistological analysis of metastatic tumors, we detected nuclear beta-catenin in 20% of lethal CaP cases, suggesting a more common role for beta-catenin in advanced disease than would be predicted by its mutation rate. Interestingly, beta-catenin nuclear localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate. These in vivo observations likely implicate beta-catenin involvement in both normal and neoplastic prostate physiology, thus prompting our interest in further characterizing modes of beta-catenin signaling in prostate cells. Extending our previous findings, we demonstrate that transient beta-catenin over-expression stimulates T cell factor (TCF) signaling in most CaP cell lines. Further, this activity is not subject to cross- regulation by phosphoinositide-3-kinase (PI3-K)/Akt signaling, a stimulatory pathway often upregulated in CaP upon PTEN inactivation. Consistent with a previous report, we observed that transient beta-catenin overexpression enhances AR-mediated transcription off two natural target gene promoters. However, we were unable to recapitulate beta-catenin-induced stimulation of ectopically expressed AR in AR-negative cells, suggesting that other AR-associated factors are required for this activity. Although LNCaP cells are capable of this mode of AR co-stimulation, stable expression of mutant beta-catenin did not alter their proliferative response to androgen. In total, our characterization of beta-catenin signaling in CaP reveals the complex nature of its activity in prostate tissue, indicating that beta-catenin potentially contributes to multiple stimulatory inputs required for disease progression.
引用
收藏
页码:2679 / 2694
页数:16
相关论文
共 77 条
  • [1] beta-catenin is a target for the ubiquitin-proteasome pathway
    Aberle, H
    Bauer, A
    Stappert, J
    Kispert, A
    Kemler, R
    [J]. EMBO JOURNAL, 1997, 16 (13) : 3797 - 3804
  • [2] Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity
    Ali, IU
    Schriml, LM
    Dean, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (22): : 1922 - 1932
  • [3] Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium
    Barker, N
    Huls, G
    Korinek, V
    Clevers, H
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) : 29 - 35
  • [4] Bubendorf L, 1999, CANCER RES, V59, P803
  • [5] Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO
  • [6] 2-W
  • [7] The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors
    Crawford, HC
    Fingleton, BM
    Rudolph-Owen, LA
    Goss, KJH
    Rubinfeld, B
    Polakis, P
    Matrisian, LM
    [J]. ONCOGENE, 1999, 18 (18) : 2883 - 2891
  • [8] INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B
    CROSS, DAE
    ALESSI, DR
    COHEN, P
    ANDJELKOVICH, M
    HEMMINGS, BA
    [J]. NATURE, 1995, 378 (6559) : 785 - 789
  • [9] The androgen receptor: genetic considerations in the development and treatment of prostate cancer
    Cude, KJ
    Dixon, SC
    Guo, Y
    Lisella, J
    Figg, WD
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (05): : 419 - 426
  • [10] Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO